Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
Autore:
Ko, YJ; Small, EJ; Kabbinavar, F; Chachoua, A; Taneja, S; Reese, D; DePaoli, A; Hannah, A; Balk, SP; Bubley, GJ;
Indirizzi:
Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USAHarvard Univ Boston MA USA 02215 Deaconess Med Ctr, Boston, MA 02215 USA Sugen, S San Francisco, CA 94080 USA Sugen S San Francisco CA USA 94080Sugen, S San Francisco, CA 94080 USA NYU, Med Ctr, New York, NY 10016 USA NYU New York NY USA 10016NYU, Med Ctr, New York, NY 10016 USA Univ Calif Los Angeles, Los Angeles, CA 90095 USA Univ Calif Los Angeles Los Angeles CA USA 90095 Los Angeles, CA 90095 USA Univ Calif San Francisco, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 4, volume: 7, anno: 2001,
pagine: 800 - 805
SICI:
1078-0432(200104)7:4<800:AMPISO>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
FACTOR-B CHAINS; BETA-RECEPTOR; SIGNAL-TRANSDUCTION; CELL-LINE; FACTOR-A; ESTRAMUSTINE; LEUKEMIA; ALPHA; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Bubley, GJ Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, HIM-1047,330 Brookline Ave, Boston, MA 02215 USA Harvard Univ HIM-1047,330 BrooklineAve Boston MA USA 02215 USA
Citazione:
Y.J. Ko et al., "A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer", CLIN CANC R, 7(4), 2001, pp. 800-805

Abstract

In a multi-institutional Phase II trial, we evaluated the efficacy of a platelet-derived growth factor receptor (PDGF-r) inhibitor, SU101, in patients with hormone-refractory prostate cancer. The patients received a 4-day i.v. loading dose of SU101 at 400 mg/m(2) for 4 consecutive days, followed byTO weekly infusions at 400 mg/m2. The primary study end points were a decline in prostate-specific antigen (PSA) and a decrease in measurable tumor. Secondary end points were time to progression and an effect on pain as measured by the Brief Pain Survey, Expression of PDGF-r was examined in both metastatic and archival primary prostate tumor samples. Forty-four patients were enrolled at four centers, The median age was 72 years, the median PSA was 223 ng/ml, and 21 patients had at least one prior chemotherapy, Thirty-nine patients are evaluable for PSA, and three patients demonstrated a PSA decline >50% from baseline (55-99.9% decrease). The median time to progression was 90 days, Of 19 patients evaluable for measurable disease, 1 patient had a partial response. Nine of 35 evaluable patients had significant improvement in pain. The most frequent adverse events were asthenia (75%), nausea (55%), anorexia (50%), and anemia (41%). PDGF-r expression was detected in 80% of the metastases and 88% of primary prostate cancers, The results ofthis trial may warrant further clinical studies with other PDGF-r inhibitors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 17:32:02